MRNA Just Bounced 7% Into a Wall of Sellers — $135 Separates a Higher Base From a Lower High

Moderna is up more than 7% to about $146 this afternoon, but the bounce has a tell: every order size is net selling into it. This is not a clean continuation. It is a contested fight over what a company that tripled on one cancer-vaccine readout is actually worth.

The chart has stopped being a rocket and turned into a negotiation. And like any negotiation, it has a line that decides who walks away trapped.

The event that rewrote the chart

On August 19, Moderna and partner Merck reported positive interim Phase 3 results for a personalized mRNA cancer vaccine — intismeran, combined with Keytruda — in high-risk melanoma. Moderna's stock surged more than 155% that day, a record pop, because it was the first Phase 3 success for a cancer treatment vaccine, clearing the way to ask regulators for approval. For a company whose shares had crumbled for years as COVID vaccine revenue vanished, it was a wholesale rewrite of the story — the cancer vaccine win restored Wall Street's faith in a name that had lost it.

That single readout took the stock from a 52-week low near $22 to a high of $176.66 in the space of a month — up around 130% in the last twenty sessions alone and more than 300% year to date.

Here is where the tape gets honest

The important part is what happened after the pop, not on it. Moderna printed about $176.66 and then went nowhere but down — it has spent the period since drifting to a pullback of roughly 18% below that high, around the $144 area into early September. Last five days? The stock is effectively flat to slightly negative even with today's pop.

That is a correction sitting right underneath the catalyst high, carving lower highs. Today's action sits inside that correction, not outside it.

Today's session is the kind of bar that deserves a second look: it opened at $138, dipped to $135.01, ran to $149.71, and now sits near $146 with an intraday range of nearly 11%. A 7% pop on this stock is a big day; an 11% round-trip in one session is the signature of a market that can't decide. And the money-flow readout leans toward decided: net outflows showed up in every cohort — retail, medium, large, and block orders all sold more than they bought into the rally.

A bounce being sold into is not the same as a fresh breakout being confirmed. Participation is present; conviction is not.

The line that actually matters

Everything now runs through the $135 area. That is today's low at $135.01, sitting just under yesterday's close of $136.62. It has memory only because it is the first floor the post-pop correction has actually defended this week — the spot where buyers stepped back in after the recent drift.

Hold $135 and the bounce keeps its fuel: the path reopens through today's $150 high, and the real gate above that is the $176.66 catalyst high. That is the level a new leg needs to reclaim on heavier volume — until price takes that back, every pop is a lower high waiting to be rejected.

Lose $135 and the picture flips. This becomes a failed bounce inside a longer correction, and a reminder of what a vertical move leaves behind: a run that climbed from well below $100 to $176 in weeks leaves far fewer tested floors underneath. Below $135, the chart's support gets thin fast.

Scenario	Trigger	Path	Invalidation	Horizon
Bounce extends	Hold $135–136	Reclaim $150, then test the $176.66 catalyst high	Losing $135 closes the door	Sessions to weeks
Full re-cock	Close back above $176.66 on expanding volume	New leg, prior high becomes a floor	Failing to hold that reclaim	Weeks
Lower high confirmed	Break $135 on volume	Correction deepens; thinner floors below	Reclaiming $135	Sessions

The verdict

The clock here is the daily chart, not a ten-minute bar. Wall Street's formal view is a Hold — seven buys against five sells — and the consensus price target sits far below where the stock trades, a reminder that price has run well ahead of what sell-side models have added up. That gap is exactly why the technical level matters more than usual: when fundamentals haven't caught up, the chart is the only arbiter of the disagreement.

Hold $135 and Moderna's higher base stays in play, with $176.66 as the confirmation line. Lose $135 and the post-catalyst breakout becomes a lower-high distribution, and the correction gets room to run. The next few sessions — not the headline — decide which side is right.

Hold $135 and the re-rating continues. Lose it and the chart takes back what the news gave it.